<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9996">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702689</url>
  </required_header>
  <id_info>
    <org_study_id>080148</org_study_id>
    <secondary_id>08-C-0148</secondary_id>
    <nct_id>NCT00702689</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease</brief_title>
  <official_title>A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Chronic graft-versus-host disease (GVHD) is a common complication of stem cell transplant,
      resulting from the donor's immune cells attacking the cells of the body of the recipient.
      One effect of GVHD is fibrosis (scarring) of the skin that can lead to impaired function,
      decreased quality of life and increased risk of death. This is known as sclerotic skin
      changes of GVHD, or sclerodermatous graft versus host disease (ScGVHD).

      Imatinib mesylate (Gleevec) is a drug that has been approved by the Food and Drug
      Administration to treat cancer in humans and fibrosing conditions in animals.

      Objectives:

      To see if imatinib mesylate can improve ScGVHD and evaluate its effect on other GVHD
      symptoms

      To assess the side effects of imatinib mesylate in patients with GVHD

      To evaluate blood, body fluids and tissue samples in patients to try to better understand
      the biology of ScGVHD

      Eligibility:

      Patients 4 years of age and older with ScGVHD

      Design:

      Initial treatment: Participants take imatinib mesylate tablets once a day for up to 6
      months, as long as their GVHD does not get worse and they do not develop unacceptable side
      effects of the drug.

      Evaluations: Participants are evaluated at 1, 3 and 6 months at the National Institutes of
      Health (NIH) Clinical Center with procedures that may include the following:

      Medical history and physical examination

      Blood and urine tests

      Lung function test

      Skin biopsy

      Magnetic resonance imaging (MRI) scan

      Specialty consultations (e.g., physical or rehabilitative therapy, dentist, eye doctor,
      dermatologist)

      Electrocardiogram (EKG)

      Echocardiogram (ultrasound test of the heart)

      Muga scan (nuclear medicine test of the heart)

      Quality-of-life questionnaires

      Apheresis (procedure for collecting quantities of white blood cells)

      Office visits with local physician once a week for 1 month, then once every 2 weeks for 5
      months

      Followup visits at National Institutes of Health (NIH) every 6 months for 1 year

      Continuing treatment: Patients who improve continue to receive imatinib mesylate for up to 6
      months after their best response and are followed for up to 2 years. Patients who continue
      to respond or who become worse after stopping treatment may receive additional treatment for
      up to 2 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Chronic graft versus host disease (cGVHD) is a major complication of allogeneic stem cell
      transplant (alloHSCT). The sclerotic skin manifestations of chronic cutaneous GVHD (ScGVHD)
      can lead to significant functional impairment and no satisfactory therapy exists to
      adequately treat this form of cGVHD.

      Imatinib mesylate (Gleevec) is a small molecule tyrosine kinase inhibitor with potent
      activity against platelet derived growth factor receptor (PDGFR) signaling, a key cytokine
      pathway which has been implicated in fibrotic disease in general, and in extensive cGVHD in
      particular.

      We hypothesize that treatment with imatinib mesylate will reduce the sclerotic
      manifestations of cGVHD as assessed by quantitative range of motion assessment of an
      affected joint.

      Objectives:

      Primary Objective:

      To investigate whether imatinib mesylate results in clinical improvement in skin fibrosis in
      children and adults with ScGVHD using range of motion assessment of affected joints.

      To determine if imatinib mesylate 200 mg daily is tolerated by patients with cGVHD.

      Secondary Objectives:

      To assess toxicity associated with imatinib mesylate in patients with cGVHD.

      To establish outcome criteria for the evaluation of ScGVHD using multi-modality objective
      and subjective assessments, including magnetic resonance imaging, skin scoring, and patient
      self-reported measures.

      To evaluate biomarkers of disease activity and correlative response measures to treatment
      with imatinib mesylate.

      To assess quality of life and functional measures of disease activity and to evaluate
      changes through the course of therapy.

      To evaluate the response of other organ manifestations affected by cGVHD to treatment with
      imatinib mesylate.

      To evaluate steady-state pharmacokinetics of imatinib mesylate in the cGVHD patient
      population.

      Eligibility:

      Patients age 4 years of age or older with the diagnosis of ScGVHD.

      Design:

      This is an open-label, pilot study of imatinib mesylate.

      Treatment cycles are 28-day cycles with no rest period between cycles.

      A target of 10 evaluable patients will be enrolled on this trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A change in ROM is 25% or greater from baseline. A partial response required improvement in 25% or more in ROM. Progression required 25% or greater loss of ROM.Patients with negative values in the Table are those who lost ROM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>41 months, 27 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Sclerotic Graft Versus Host Disease</condition>
  <condition>Imatinib Mesylate</condition>
  <arm_group>
    <arm_group_label>Imatinib mesylate in patients with cGVHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec, STI571(Imatinib Mesylate)</intervention_name>
    <description>Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)</description>
    <arm_group_label>Imatinib mesylate in patients with cGVHD</arm_group_label>
    <other_name>Gleevec</other_name>
    <other_name>ST1571</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Sclerodermatous graft versus host disease (ScGVHD) manifesting after at least 100
             days following allogeneic hematopoietic stem cell transplantation is considered
             diagnostic for chronic graft versus host disease (cGVHD) according to National
             Institutes of Health (NIH) cGVHD Consensus Statement diagnostic criteria.

        This diagnosis can be made clinically or by histopathology. The diagnosis must be
        confirmed by the principal investigator (PI), or lead associate investigator (LAI).

        Skin biopsies will be reviewed by the National Cancer Institute (NCI) Laboratory of
        Pathology to confirm the diagnosis of ScGVHD.

          -  Patients must have measurable limitation in range of motion, defined as ScGVHD with
             or without fasciitis, restricting range of motion (ROM) of at least one joint with a
             minimum deficit of 25 percent.

          -  Prior therapy: Patients must have cGVHD refractory to at least one treatment regimen
             for cGVHD.

        One prior regimen must have included systemic corticosteroids at the equivalent prednisone
        dosing of 1mg/kg/day times 14 days.

        Patients in whom calcineurin inhibitors or corticosteroids are medically contraindicated
        may also be eligible for enrollment.

        Patients who have had stabilization of disease on calcineurin inhibitors or steroids, but
        in whom these medications cannot be tapered without disease flare are also eligible.

        Patient must be on stable or tapering immunosuppressive regimen for at least one month.

          -  Age: 4 years of age or older at the time of enrollment. Lower age limit set by lower
             established age limit norms of ROM scores for measurement criteria.

          -  Life expectancy of greater than 6 months.

          -  Karnofsky greater than or equal to 60 percent.

          -  Patients must be platelet transfusion and growth factor independent at the time of
             study entry.

        Patients must have adequate organ and marrow function as defined below. Patients with
        Gilbert syndrome are excluded from the requirement of a normal bilirubin.

        (Gilbert syndrome is found in 3-10 percent of the general population, and is characterized
        by mild, chronic unconjugated hyperbilirubinemia in the absence of liver disease or overt
        hemolysis).

          -  absolute neutrophil count greater than or equal to 1,000/mcL

          -  platelets greater than or equal to 50,000/mcL

          -  total bilirubin less than 3 times upper limit of normal

          -  aspartate aminotransferase (AST)serum glutamic oxaloacetic transaminase
             (SGOT)/alanine aminotransferase (ALT)serum glutamic pyruvic transaminase (SGPT) less
             than 5 times upper limit of normal

          -  creatinine age-adjusted within normal limits

        OR

          -  creatinine clearance greater than 20mL/min/1.73 m^2 for adults and pediatric patients
             with body surface area (BSA) greater than 0.97 m^2 with creatinine levels above
             institutional normals and greater than or equal to 40 mL/min 1.73 m^2 for pediatric
             patients with BSA less than 0.97 m^2.

          -  Age less than 5 years old Maximum Serum Creatinine 0.8 mg/dL

          -  Age 5 or less than 10 years old Maximum Serum Creatinine 1.0 mg/dL

          -  Age 10 or less than 15 years old Maximum Serum Creatinine 1.2 mg/dL

          -  Age 15 years old or greater Maximum Serum Creatinine 1.5 mg/dL

          -  Normal cardiac function for age as determined by echocardiogram (ECHO) or multi-gated
             acquisition scan (MUGA) (normal left ventricular (LV) function as measured by
             ejection fraction or shortening fraction).

          -  The effects of imatinib mesylate on the developing human fetus at the recommended
             therapeutic dose are unknown.

        For this reason, women of child-bearing potential and men must agree to use adequate
        contraception (hormonal or barrier method of birth control; abstinence) prior to study
        entry, for the duration of study participation, and for six months following completion of
        therapy.

        Should a woman become pregnant or suspect she is pregnant while participating in this
        study, she should inform her treating physician immediately.

          -  Ability to understand and the willingness to sign a written informed consent
             document.

        All patients or their legal guardian (for patients less than 18 years old) must sign an
        institutional review board (IRB) approved document of informed consent (chronic graft
        versus host disease (cGVHD) natural history or any National Cancer Institute (NCI)
        protocol allowing for screening procedures) prior to performing studies to determine
        patient eligibility.

        After confirmation of patient eligibility all patients or their legal guardian must sign
        the protocol-specific informed consent.

        Pediatric patients will be included in age appropriate discussions and age appropriate
        assent will be obtained in accordance with National Institutes of Health (NIH) guidelines.

          -  Durable Power of Attorney (DPA): All patients 18 years of age at the time of
             enrollment will be offered the opportunity to assign DPA so that another person can
             make decisions about their medical care if they become incapacitated or cognitively
             impaired.

        EXCLUSION CRITERIA:

          -  Patients who have had chemotherapy, radiotherapy, or immunotherapy within 4 weeks (6
             weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have
             not recovered from adverse events due to agents administered more than 4 weeks
             earlier.

          -  Patients may not be receiving any other investigational agents, including
             extracorporeal photopheresis.

        Patients may not have received monoclonal antibody therapy within 6 weeks.

          -  Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse
             events.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to imatinib mesylate.

          -  Patients receiving any of the following medications or substances that are inhibitors
             or inducers of P450 3A4 are ineligible.

        Use of the following medications must be discontinued at least two weeks prior to starting
        therapy:

          -  Alfuzosin

          -  Aprepitant

          -  Carbamazepine

          -  Clarithromycin

          -  Eletriptan

          -  Erythromycin

          -  Pimozide

          -  St John's Wort

          -  Warfarin

          -  A list of medications and substances known or with the potential to interact with the
             P450 3A4 isoenzyme is provided in Section 8.

        Imatinib mesylate is likely to increase the blood level of drugs that are substrates of
        CYP2C9, CYP2D6 and CYP3A4/5.

        Close monitoring is warranted when using agents metabolized by these enzymes. Grapefruit
        juice should not be consumed while on therapy.

          -  Prior treatment with imatinib mesylate or other tyrosine kinase inhibitor after the
             date of transplant.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, pulmonary, hepatic, or other organ dysfunction, or psychiatric
             illness/social situations that would limit compliance with study requirements or
             compromise the patient's ability to tolerate protocol therapy.

          -  Pregnant women are excluded from this study because imatinib mesylate is an agent
             with the potential for teratogenic or abortifacient effects.

        Because there is an unknown but potential risk for adverse events in nursing infants
        secondary to treatment of the mother with imatinib mesylate, breastfeeding should be
        discontinued if the mother is treated with imatinib mesylate.

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             imatinib mesylate and the possibility of associated severe immunosuppression.

          -  Patients with active hepatitis C or hepatitis B infection as defined by
             seropositivity for hepatitis C or hepatitis B (HepBSAg) and elevated transaminases,
             as GVHD manifestations involving the liver will be indistinguishable and
             drug-toxicity uninterpretable.

          -  Persistent malignancy, requiring ongoing therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward W Cowen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute (NCI), 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-C-0148.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 29, 2015</lastchanged_date>
  <firstreceived_date>June 19, 2008</firstreceived_date>
  <firstreceived_results_date>September 5, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Edward Cowen, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Skin Sclerosis</keyword>
  <keyword>Graft Versus Host Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Imatinib Mesylate in Patients With cGVHD</title>
          <description>Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recurrent malignancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Imatinib Mesylate in Patients With cGVHD</title>
          <description>Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42.59" spread="17.49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months</title>
        <description>A change in ROM is 25% or greater from baseline. A partial response required improvement in 25% or more in ROM. Progression required 25% or greater loss of ROM.Patients with negative values in the Table are those who lost ROM.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate in Patients With cGVHD</title>
            <description>Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months</title>
            <description>A change in ROM is 25% or greater from baseline. A partial response required improvement in 25% or more in ROM. Progression required 25% or greater loss of ROM.Patients with negative values in the Table are those who lost ROM.</description>
            <units>Percent change from baseline</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pt 2 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt 3 3mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA">The overall response for patient # 3 is progressive disease. Patient was NOT evaluated at 6 months because patient progressed at the 3 month time point, so there is no measurement at 6 months, but patient is still considered progressive disease.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt 7 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt 8 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt10 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt12 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt13 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt14 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt15 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt16 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt17 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt18 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt19 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pt20 6mo response% change in deficit from baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
        <time_frame>41 months, 27 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate in Patients With cGVHD</title>
            <description>Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adverse Events</title>
            <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Imatinib Mesylate in Patients With cGVHD</title>
          <description>Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema::head and neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema:: trunk/genital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with unknown ANC::Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)::Whole body/generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Head/headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify, Pulmonary edema)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::External ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms-Other (Specify, cold intolerance; sleep walking)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema::head and neck</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hyperglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="26" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)::Whole body/generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft tissue - Other (Specify, hand &amp; jaw cramps; hand &amp; jaw cramps, intermittent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain::Bone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain::Joint</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain::Muscle</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>leukoencephalopathy (radiographic findings)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain::Head/headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mood alteration::Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify, intermt. bilateral hands &amp; L. hip)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain::Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Cowen, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-4299</phone>
      <email>cowene@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
